Literature DB >> 34110531

The novel index using preoperative C-reactive protein and neutrophil-to-lymphocyte ratio predicts poor prognosis in patients with pancreatic cancer.

Tomohiko Taniai1, Koichiro Haruki2, Kenei Furukawa1, Shinji Onda1, Jungo Yasuda1, Yoshihiro Shirai1, Takeshi Gocho1, Mitsuru Yanagaki1, Ryoga Hamura1, Hiroaki Shiba1, Toru Ikegami1.   

Abstract

BACKGROUND: Several kinds of systemic inflammatory response, classified into two types: C-reactive protein (CRP)-based type and blood cell count-based type, were reported as a prognostic indicator in patients with pancreatic cancer (PC). However, there is no consensus which types is more sensitive predictor in patients with PC. Therefore, we here developed a novel biomarker, C-NLR, which consists of both CRP and neutrophil-to-lymphocyte ratio (NLR), and we evaluated the prognostic significance of C-NLR in patients with PC after pancreatic resection.
METHODS: A total of 217 patients was comprised in this study. We retrospectively investigated the relation between C-NLR and disease-free survival (DFS) and overall survival (OS) after pancreatic resection.
RESULTS: Optimal cutoff level of C-NLR was defined as 0.206 by a ROC analysis. By multivariate analysis, age (P = 0.024), TNM stage (P < 0.001), and C-NLR (HR: 1.373, 95% CI: 1.005-1.874, P = 0.046) were independent predictors of DFS, whereas TNM stage (P = 0.016) and C-NLR (HR: 1.468, 95% CI: 1.042-2.067, P = 0.028) were independent predictors of OS.
CONCLUSION: Preoperative C-NLR can be a prognostic indicator in patients with PC after pancreatic resection, suggesting the importance of both CRP and blood cell count in predicting therapeutic outcomes.

Entities:  

Keywords:  C-reactive protein; Neutrophil-to-lymphocyte ratio; Pancreatic cancer; Prognosis; Systemic inflammation

Year:  2021        PMID: 34110531     DOI: 10.1007/s10147-021-01964-2

Source DB:  PubMed          Journal:  Int J Clin Oncol        ISSN: 1341-9625            Impact factor:   3.402


  23 in total

1.  C-Reactive Protein-based Prognostic Measures Are Superior at Predicting Survival Compared with Peripheral Blood Cell Count-based Ones in Patients After Curative Resection for Pancreatic Cancer.

Authors:  Yuki Fujiwara; Koichiro Haruki; Hiroaki Shiba; Ryoga Hamura; Takashi Horiuchi; Yoshihiro Shirai; Kenei Furukawa; Takeshi Gocho; Katsuhiko Yanaga
Journal:  Anticancer Res       Date:  2018-11       Impact factor: 2.480

2.  Preoperative platelet to lymphocyte ratio predicts outcome of patients with pancreatic ductal adenocarcinoma after pancreatic resection.

Authors:  Yoshihiro Shirai; Hiroaki Shiba; Taro Sakamoto; Takashi Horiuchi; Koichiro Haruki; Yuki Fujiwara; Yasuro Futagawa; Toya Ohashi; Katsuhiko Yanaga
Journal:  Surgery       Date:  2015-05-29       Impact factor: 3.982

3.  Cancer treatment and survivorship statistics, 2019.

Authors:  Kimberly D Miller; Leticia Nogueira; Angela B Mariotto; Julia H Rowland; K Robin Yabroff; Catherine M Alfano; Ahmedin Jemal; Joan L Kramer; Rebecca L Siegel
Journal:  CA Cancer J Clin       Date:  2019-06-11       Impact factor: 508.702

4.  The C-reactive Protein to Albumin Ratio Predicts Long-Term Outcomes in Patients with Pancreatic Cancer After Pancreatic Resection.

Authors:  Koichiro Haruki; Hiroaki Shiba; Yoshihiro Shirai; Takashi Horiuchi; Ryota Iwase; Yuki Fujiwara; Kenei Furukawa; Takeyuki Misawa; Katsuhiko Yanaga
Journal:  World J Surg       Date:  2016-09       Impact factor: 3.352

5.  S-1 vs. gemcitabine as an adjuvant therapy after surgical resection for ductal adenocarcinoma of the pancreas.

Authors:  Takehiro Okabayashi; Yasuo Shima; Jun Iwata; Sojiro Morita; Tatsuaki Sumiyoshi; Akihito Kozuki; Teppei Tokumaru; Tatsuo Iiyama; Takuhiro Kosaki; Michiya Kobayashi; Kazuhiro Hanazaki
Journal:  World J Surg       Date:  2014-11       Impact factor: 3.352

6.  The National Cancer Data Base report on pancreatic cancer.

Authors:  J E Niederhuber; M F Brennan; H R Menck
Journal:  Cancer       Date:  1995-11-01       Impact factor: 6.860

Review 7.  Inflammation and cancer: advances and new agents.

Authors:  Shanthini M Crusz; Frances R Balkwill
Journal:  Nat Rev Clin Oncol       Date:  2015-06-30       Impact factor: 66.675

8.  Increased neutrophil-lymphocyte ratio is a poor prognostic factor in patients with primary operable and inoperable pancreatic cancer.

Authors:  M Stotz; A Gerger; F Eisner; J Szkandera; H Loibner; A L Ress; P Kornprat; W AlZoughbi; W A Zoughbi; F S Seggewies; C Lackner; T Stojakovic; H Samonigg; G Hoefler; M Pichler
Journal:  Br J Cancer       Date:  2013-06-25       Impact factor: 9.075

9.  Systemic Immune-Inflammation Index (SII) Predicts Poor Survival in Pancreatic Cancer Patients Undergoing Resection.

Authors:  Gerd Jomrich; Elisabeth S Gruber; Daniel Winkler; Marlene Hollenstein; Michael Gnant; Klaus Sahora; Martin Schindl
Journal:  J Gastrointest Surg       Date:  2019-03-28       Impact factor: 3.452

10.  Clinical Implication of Inflammation-Based Prognostic Score in Pancreatic Cancer: Glasgow Prognostic Score Is the Most Reliable Parameter.

Authors:  Suguru Yamada; Tsutomu Fujii; Norimitsu Yabusaki; Kenta Murotani; Naoki Iwata; Mitsuro Kanda; Chie Tanaka; Goro Nakayama; Hiroyuki Sugimoto; Masahiko Koike; Michitaka Fujiwara; Yasuhiro Kodera
Journal:  Medicine (Baltimore)       Date:  2016-05       Impact factor: 1.889

View more
  5 in total

1.  Predictive value of albumin combined with neutrophil-to-lymphocyte ratio for efficacy and safety profiles in patients with pancreatic ductal adenocarcinoma receiving liposomal irinotecan plus 5-fluorouracil and leucovorin.

Authors:  Yen-Yang Chen; Shun-Wen Hsueh; Shih-Hung Yang; Sz-Chi Chiu; Nai-Jung Chiang; Tai-Jan Chiu; Chung-Pin Li; Li-Yuan Bai; Chang-Fang Chiu; Shih-Chang Chuang; Yan-Shen Shan; De-Chuan Chan; Li-Tzong Chen; Chia-Jui Yen; Cheng-Ming Peng; Jen-Shi Chen; Wen-Chi Chou
Journal:  Am J Cancer Res       Date:  2022-09-15       Impact factor: 5.942

2.  Pancreatic fibrosis, acinar atrophy and chronic inflammation in surgical specimens associated with survival in patients with resectable pancreatic ductal adenocarcinoma.

Authors:  Leena Kylänpää; Hanna Seppänen; Taija Korpela; Ari Ristimäki; Marianne Udd; Tiina Vuorela; Harri Mustonen; Caj Haglund
Journal:  BMC Cancer       Date:  2022-01-03       Impact factor: 4.430

3.  A nomogram combining inflammatory markers and clinical factors predicts survival in patients with diffuse glioma.

Authors:  Ping Yan; Jian-Wen Li; Li-Gen Mo; Qian-Rong Huang
Journal:  Medicine (Baltimore)       Date:  2021-11-24       Impact factor: 1.817

4.  Combination of C-Reactive Protein and Neutrophil-to-Lymphocyte Ratio as a Novel Prognostic Index in Patients With Bladder Cancer After Radical Cystectomy.

Authors:  Yidi Wang; Keyi Wang; Jinliang Ni; Houliang Zhang; Lei Yin; Yifan Zhang; Huajuan Shi; Tao Zhang; Naichun Zhou; Weipu Mao; Bo Peng
Journal:  Front Oncol       Date:  2021-12-02       Impact factor: 6.244

5.  Multiplexed Detection of Pancreatic Cancer by Combining a Nanoparticle-Enabled Blood Test and Plasma Levels of Acute-Phase Proteins.

Authors:  Damiano Caputo; Alessandro Coppola; Erica Quagliarini; Riccardo Di Santo; Anna Laura Capriotti; Roberto Cammarata; Aldo Laganà; Massimiliano Papi; Luca Digiacomo; Roberto Coppola; Daniela Pozzi; Giulio Caracciolo
Journal:  Cancers (Basel)       Date:  2022-09-25       Impact factor: 6.575

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.